James Mills, in Manchester, KY - Physical Medicine & Rehabilitation

James Mills, is a Physical Medicine & Rehabilitation physician based in Manchester, Kentucky. James Mills is licensed to practice in Kentucky (license number A03690) and his current practice location is 485 Memorial Dr Ste 2, Manchester, Kentucky. He can be reached at his office (for appointments etc.) via phone at (606) 599-1709.

NPI number for James Mills is 1154886240 and his current mailing address is 485 Memorial Dr Ste 2, Manchester, Kentucky. He does not participate in medicare program and thus does not accept medicare assignments. His NPI Number is 1154886240.

Contact Information

	James Mills,
	485 Memorial Dr Ste 2, Manchester, KY 40962-9111
	(606) 599-1709
	Not Available

Physician's Profile

Full Name	James Mills
Gender	Male
Speciality	Physical Medicine & Rehabilitation
Location	485 Memorial Dr Ste 2, Manchester, Kentucky
Accepts Medicare Assignments	Does not participate in Medicare Program. He may not accept medicare assignment.

NPI Data:

NPI Number: 1154886240
Provider Enumeration Date: 02/04/2019
Last Update Date: 02/04/2019

Medical Identifiers

Medical identifiers for James Mills such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1154886240	NPI	-	NPPES

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
208100000X	Physical Medicine & Rehabilitation	A03690 (Kentucky)	Primary

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. James Mills is NOT enrolled with medicare and thus cannot prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
James Mills, 485 Memorial Dr Ste 2, Manchester, KY 40962-9111 Ph: (606) 599-1709	James Mills, 485 Memorial Dr Ste 2, Manchester, KY 40962-9111 Ph: (606) 599-1709

News Archive

Invatec welcomes first clinical results of Drug Eluting Balloon

Invatec, a comprehensive innovator of interventional products, welcomed the first clinical results of the Drug Eluting Balloon (DEB), IN.PACT Amphirion, for complex Critical Limb Ischemia (CLI) in Below the Knee (BtK).

Researchers profile genes in acutely ill idiopathic pulmonary fibrosis patients

The first findings from a one-of-a-kind, patient-driven effort to provide lung tissue for research might help doctors predict when patients with idiopathic pulmonary fibrosis (IPF) are becoming dangerously ill and also could point the way to interventions that could sustain them until life-saving transplants can be performed.

Australia's swine flu alert level may be raised a notch

As Australia's number of confirmed cases of influenza A H1N1 (swine flu) continues to soar - the toll is now 1,211 - there is now the very real possibility that the swine flu alert level will be raised a notch.

Huntington's disease drug clears initial hurdles - raising hopes

Huntington's disease is a genetic disorder that affects the brain progressively and has no known cure till date. In a breakthrough, the first drug that can target and reduce the cause behind this dreaded disease has been found to be effective, safe and well tolerated in a human clinical trial that was conducted by UCL scientists.

James Mills, - Physical Medicine & Rehabilitation in Manchester, KY